# Periodontitis-Induced Immune Reprogramming: Implications for Cancer Immunotherapy Response

**Authors:** Claudia Florina Bogdan-Andreescu, Ștefan-Dimitrie Albu, Dan Alexandru Slăvescu, Lucia Bubulac, Viorica Tudor, Oana Botoacă, Andreea-Mariana Bănățeanu, Emin Cadar, Cristina-Crenguţa Albu

PMC · DOI: 10.3390/biomedicines14020480 · Biomedicines · 2026-02-22

## TL;DR

This paper explores how chronic periodontitis affects the immune system and may influence cancer immunotherapy outcomes.

## Contribution

It highlights the systemic immune reprogramming caused by periodontitis and its implications for immunotherapy response.

## Key findings

- Periodontitis elevates proinflammatory mediators like IL-1β, IL-6, and TNF-α.
- Chronic inflammation alters T-cell polarization and promotes myeloid cell training.
- Controlling periodontal inflammation may reduce systemic inflammation but clinical evidence is limited.

## Abstract

Background: Chronic periodontitis is a prevalent inflammatory disease. It goes beyond the oral cavity, exerting systemic immunomodulatory effects through continuous low-grade inflammation, microbial dysbiosis, and cytokine spillover. Accumulating evidence suggests that the immunological consequences of periodontitis may influence systemic immune homeostasis and alter responses to cancer immunotherapies, specifically checkpoint blockade. Objectives: This narrative review describes how periodontal inflammation induces systemic immune reprogramming. It also investigates possible effects on the efficacy of immunotherapy. Methods: The paper synthesizes current findings on molecular and cellular mechanisms linking periodontitis to immune dysfunction. It underscores the mutual signaling pathways NF-κB, STAT3, and PD-1/PD-L1 that connect oral and systemic immunity. Results: Chronic periodontal inflammation reprograms innate and adaptive immune responses. It elevates proinflammatory mediators, such as IL-1β, IL-6, and TNF-α. It alters T-cell polarization and promotes myeloid cell “training”. This process may lead to immune exhaustion, impaired antigen presentation, and treatment resistance. Preclinical and new clinical data suggest that controlling periodontal inflammation may partially reduce systemic inflammatory burden, although clinical evidence in immunotherapy-treated cancer cohorts remains limited. Conclusions: Periodontal health should be considered in the management of immunotherapy. This can facilitate new studies that integrate oral and systemic immunology. Understanding the two-way link between periodontal inflammation and systemic immune reprogramming may offer fresh opportunities for personalized immunomodulation and combined interventions.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), IL6 (interleukin 6), TNF (tumor necrosis factor), NFKB1 (nuclear factor kappa B subunit 1), STAT3 (signal transducer and activator of transcription 3), PDCD1 (programmed cell death 1), CD274 (CD274 molecule)
- **Diseases:** periodontitis (MONDO:0005076), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CRP (C-reactive protein, pentraxin-related) [NCBI Gene 396842] {aka PTX1}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, FOXP3 (forkhead box P3) [NCBI Gene 444998], IL6 (interleukin 6) [NCBI Gene 399500] {aka IL-6}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 396750] {aka ICAM-1}, ACLY (ATP citrate lyase) [NCBI Gene 100125957] {aka ACL}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 397286], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 396925], CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], PIK3AP1 (phosphoinositide-3-kinase adaptor protein 1) [NCBI Gene 118788] {aka BCAP}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, NOD2 (nucleotide binding oligomerization domain containing 2) [NCBI Gene 100125838], GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 733648], TNF (tumor necrosis factor) [NCBI Gene 397086] {aka TNFSF2, TNFa}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CRP (C-reactive protein) [NCBI Gene 100620468], NECTIN1 (nectin cell adhesion molecule 1) [NCBI Gene 5818] {aka CD111, CLPED1, ED4, HIgR, HV1S, HVEC}
- **Diseases:** diabetes (MESH:D003920), dysbiosis (MESH:D064806), endothelial dysfunction (MESH:D014652), Tumor (MESH:D009369), inflammatory response (MESH:D018746), asthma (MESH:D001249), hyperglycemia (MESH:D006943), metabolic syndrome (MESH:D024821), injury to (MESH:D014947), oral condition (MESH:D020763), Periodontitis (MESH:D010518), Chronic Inflammation (MESH:D007249), mitochondrial dysfunction (MESH:D028361), myeloid (MESH:D007951), metabolic diseases (MESH:D008659), gingival lesions (MESH:D005882), oral squamous cell carcinoma (MESH:D000077195), NSCLC (MESH:D002289), TAM (MESH:D020914), microbial infections (MESH:D015163), obesity (MESH:D009765), CMV (MESH:D003586), respiratory conditions (MESH:D012131), oral cancers (MESH:D009062), Fatigue (MESH:D005221), immune (MESH:D007154), Chronic Periodontitis (MESH:D055113), infection (MESH:D007239), cardiovascular disease (MESH:D002318), derived (MESH:C536408), MDSC (OMIM:601308), bone loss (MESH:D001847), cytotoxicity (MESH:D064420), alveolar bone loss (MESH:D016301), gingivitis (MESH:D005891), viral infections (MESH:D014777), atherogenesis (MESH:D050197), periodontal disease (MESH:D010510), tumor-associated macrophage (MESH:D000072716), immune dysregulation (OMIM:614878), HIV (human immunodeficiency virus) infection (MESH:D015658), sepsis (MESH:D018805), chronic (MESH:D002908), glioblastoma (MESH:D005909), -cell (MESH:D002292), musculoskeletal disorders (MESH:D009140), bacterial (MESH:D001424), oral (MESH:D020820)
- **Chemicals:** cortisol (MESH:D006854), lactate (MESH:D019344), TCA (MESH:D014233), corticosterone (MESH:D003345), mevalonate (MESH:D008798), copper (MESH:D003300), vitamin A (MESH:D014801), prostaglandin E2 (MESH:D015232), acetyl-CoA (MESH:D000105), mitochondrial reactive oxygen species (-), ATRA (MESH:D014212), reactive oxygen species (MESH:D017382), citrate (MESH:D019343), LPS (MESH:D008070)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Porphyromonas gingivalis (species) [taxon 837], gut metagenome (species) [taxon 749906], Fusobacterium nucleatum (species) [taxon 851]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938730/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938730/full.md

## References

131 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938730/full.md

---
Source: https://tomesphere.com/paper/PMC12938730